Neurotrauma Sciences, LLC., a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries, including stroke and traumatic brain injury, expanded its executive management team with key appointments: Marc de Somer, chief medical officer and Martin Rabe, executive vice president of regulatory affairs and quality assurance. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team ...